CClinicalTrials.gg
Not yet recruitingNCT06102408RESOLVEUpdated Oct 27, 2023

Relevance and Efficiency of SecOnd Line Workup for Uveitis

An observational study in Uveitis, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Central Hospital, Nancy, France · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

The first-line etiological workup is currently poorly codified, and some patients undergo sequential investigations. However, the reason which lead the clinician to perform subsequent exams, and the relevance of such exams, remain to be determined. The main objective of the study was to assess the relevance of a second-line workup of patients with uveitis.

Read the detailed description

The first-line etiological workup is currently poorly codified, with some patients undergoing extensive investigations, and other minimal etiological workup. In addition, some patients undergo sequential investigations. However, the reason which lead the clinician to perform subsequent exams, and the relevance of investigations performed after a first line workup remain to be determined. The main objective of the study was to assess the relevance of a second-line workup of patients with uveitis.Secondary objectives were to describe the reasons of these second-line workups, and to determine which exams were the most relevant, and the determinants of its realization.

02

Conditions studied

  • Uveitis

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult pateints with uveitis requiring at least one etiological workup.

Inclusion criteria

  • adult patient
  • at least one etiological workup in our center

Exclusion criteria

Exclusion Criteria:

  • only episode of acute anterior uveitis quickly responding to topical treatments
  • diagnostic ophthalmologically obvious
  • opposition to collection of data
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with only one etiological workup

    patients who underwent only one set of exams for etiological investigations of uveitis

    Other: second line investigations for uveitis etiological workup

  • Patients without diagnostic modification subsequently to the second etiological workup

    Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.

    Other: second line investigations for uveitis etiological workup

  • Patients with diagnostic modification subsequently to the second etiological workup

    Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.

    Other: second line investigations for uveitis etiological workup

Interventions

  • Othersecond line investigations for uveitis etiological workup

    Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

05

What researchers measure

Primary outcomes

  1. patients undergoing a second line etiological workup

    percentage of patients undergoing a second line etiological workup

    Time frame: through study completion, an average of 18 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Hwang DK, Chou YJ, Pu CY, Chou P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology. 2012 Nov;119(11):2371-6. doi: 10.1016/j.ophtha.2012.05.026. Epub 2012 Jul 17. PubMed 22809756 ↗
  • Dandona L, Dandona R, John RK, McCarty CA, Rao GN. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol. 2000 Jul;84(7):706-9. doi: 10.1136/bjo.84.7.706. PubMed 10873978 ↗
  • Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057. PubMed 16196117 ↗
  • Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002 Feb;46(2):309-18. doi: 10.1002/art.503. No abstract available. PubMed 11840433 ↗
  • Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014 Apr-May;13(4-5):591-4. doi: 10.1016/j.autrev.2014.01.006. Epub 2014 Jan 12. PubMed 24424168 ↗
  • de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Perard L, Cornut PL, Schneider C, Riviere S, Olle P, Pugnet G, Cathebras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Amamra N, Guerre P, Decullier E, Seve P; ULISSE group. Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). PLoS One. 2020 Feb 14;15(2):e0228918. doi: 10.1371/journal.pone.0228918. eCollection 2020. PubMed 32059021 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06102408
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Thomas MOULINET (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Oct 26, 2023
Start date
Nov 15, 2023 (estimated)
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 25, 2023 (estimated)
Last update
Oct 27, 2023

Study contacts

Thomas Moulinet, MD
Contact
t.moulinet@chru-nancy.fr
+3383155304

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion